Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Low-intensity pulsed ultrasound stimulation to treat renal fibrosis through inhibiting tubular IL-1R
Zhimin Huang, … , Xiangqing Kong, Huijuan Mao
Zhimin Huang, … , Xiangqing Kong, Huijuan Mao
Published July 29, 2025
Citation Information: JCI Insight. 2025;10(17):e186892. https://doi.org/10.1172/jci.insight.186892.
View: Text | PDF
Research Article Immunology Nephrology

Low-intensity pulsed ultrasound stimulation to treat renal fibrosis through inhibiting tubular IL-1R

  • Text
  • PDF
Abstract

Low-intensity pulsed ultrasound stimulation (LIPUS) has become increasingly appreciated for its therapeutic effect on kidney diseases. However, its role and biological mechanism in treating chronic kidney disease remain poorly defined. Here, we revealed that LIPUS was applied in a safe range with an intensity of 25–315 mW/cm2. Daily LIPUS at an intensity of 315 mW/cm2 ameliorated ischemia/reperfusion-induced (IR-induced) tubular injury and renal fibrosis, accompanied by the remarkable downregulation of IL-1R. Transcriptome sequencing showed that LIPUS significantly downregulated IL-1R and its downstream genes in IL-1β–stimulated IR-injured mice. LIPUS effectively reversed IL-1β–induced tubular injury and reduced the production of pro-fibrotic cytokines by downregulating IL-1R in vivo and in vitro. Renal proximal tubule–specific Il1r1-knockout mice exhibited milder renal tubular injury and fibrosis after IR injury. However, LIPUS did not ameliorate IR injury in proximal tubule–specific Il1r1-knockout mice. Collectively, daily LIPUS at an intensity of 315 mW/cm2 relieves IR-induced tubular injury and fibrosis, potentially by downregulating tubular IL-1R.

Authors

Zhimin Huang, Jiaxin Dong, Ziqi Fu, Li Li, Simeng Liu, Lin Wu, Honglei Guo, Ao Bian, Kang Liu, Wei Sun, Changying Xing, Steven D Crowley, Jiafa Ren, Xiangqing Kong, Huijuan Mao

×

Figure 4

LIPUS downregulates IL-1R and its downstream genes.

Options: View larger image (or click on image) Download as PowerPoint
LIPUS downregulates IL-1R and its downstream genes.
(A) Protein level of...
(A) Protein level of IL-1R in IR-induced renal tissue and its quantitative analysis. (n = 5 in each group.) (B) Protein levels of MyD88, p-NF-κB, and c-Myc in IR-induced renal tissue and their quantitative analyses (n = 5). (C) Protein level of α-SMA in MTECs induced by different IL-1β concentrations and the quantitative analysis (n = 6). (D) Protein levels of α-SMA and fibronectin in 10 pg/μL IL-1β–induced MTECs and the quantitative analyses (n = 4). (E) Protein levels of IL-1R, p-NF-κB, and c-Myc in 10 pg/μL IL-1β–induced MTECs and the quantitative analyses. (n = 5). Data information: Data are presented as mean ± SD. Statistical significance was determined by 1-way ANOVA with Tukey’s test (C) and 2-way ANOVA with Šídák’s multiple comparisons test (A, B, D, and E). *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts